Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT05239624 2026-02-19

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Phase 2 Recruiting

23 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07221942 2026-02-19

IMPROEV

Phase 2 Recruiting

97 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06483334 2026-02-18

MK-3475-04C

Phase 1/2 Active not recruiting

38 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

Clinical Trials

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

FORAGER-2

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Keynote B59

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

MK-3475-04A

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

PNeoVCA

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

IMPROEV

MK-3475-04C